Literature DB >> 688733

Clofibrate kinetics after single and multiple doses.

R Gugler, J Hartlapp.   

Abstract

The kinetics of chlorphenoxyisobutyric acid (CPIB) were studied in 5 healthy subjects after single 500-mg, 1,000-mg, and 2,000-mg doses of clofibrate, and in steady-state after 8 days' treatment with 1,000 mg twice daily. Maximum plasma concentrations of CPIB were observed 4 to 6 hr after dosing. A mean plasma half-life of 16.7 hr was recorded which was independent of dose and duration of treatment. Total plasma clearance (-Cl) calculated from area under the curve with the use of the total plasma concentration was 5.6 ml/min for the 500-and the 1,000-mg doses but increased to 6.8 ml/min for the 2,000-mg dose and was even higher (8.1 ml/min) in steady-state. This change in -Cl is a consequence of progressive reduction in the plasma protein binding of clofibrate at plasma concentrations above 50 microgram/ml, since -Cl rises in association with reduced protein binding at the high plasma concentrations measured after the 2,000-mg single dose and in steady-state. -Cl and apparent volume of distribution were identical for all doses tested when calculations were based on the nonprotein-bound CPIB concentrations only. Due to the inconsistant protein binding of CPIB, total steady-state concentrations could not be predicted from the single dose kinetic data.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 688733     DOI: 10.1002/cpt1978244432

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

2.  Pharmacokinetics of fenclofenac following single and multiple doses.

Authors:  R Henson; J G Lloyd-Jones; J D Nichols; B J Jordan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

3.  Antiviral activity of antilipidemic compounds on herpes simplex virus type 1.

Authors:  J K Mehl; D T Witiak; V V Hamparian; J H Hughes
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

4.  Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man.

Authors:  G Houin; R A Shastri; J Barre; B Pinchon; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

5.  Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: II. High sucrose-fed animals.

Authors:  A Mukhopadhyay; S T Patel; M O'Brien; S S Kokrady; H A Newman; D T Witiak; R R Lanese; J C Rice; D R Feller
Journal:  Lipids       Date:  1983-01       Impact factor: 1.880

6.  Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.

Authors:  U Abshagen; S Spörl-Radun; J Marinow
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

7.  Chemical and protein structural basis for biological crosstalk between PPARα and COX enzymes.

Authors:  Ann E Cleves; Ajay N Jain
Journal:  J Comput Aided Mol Des       Date:  2014-11-27       Impact factor: 3.686

8.  Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade.

Authors:  Manu De Rycker; John Thomas; Jennifer Riley; Stephen J Brough; Tim J Miles; David W Gray
Journal:  PLoS Negl Trop Dis       Date:  2016-04-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.